Sentiment and Southbound Buying Fuel COFOE MEDICAL (01187) Rebound, When Will a True Reversal Come?

Stock News11-19 11:59

Since November 11, shares of COFOE MEDICAL (01187) have staged a five-day winning streak in Hong Kong trading.

Between November 11 and November 17, the stock posted a maximum interval gain of 16.40%. At the same time, on-exchange activity in the H-shares increased markedly compared with before. Over the three trading days from November 13 to 17, daily volume consistently exceeded 500,000 shares, a clear step up from the levels seen over the preceding sessions.

Catalyzed by the recent third-quarter results and the market's fermenting enthusiasm for brain-computer interface concepts, the H-shares of COFOE MEDICAL — which trade at a notable discount to the A-shares and offer a higher valuation safety margin — may be embarking on a fresh run. After bottoming out and rebounding, how far can this move go?

On the tape, from November 11 to 17, the H-shares of COFOE MEDICAL gained a cumulative 10.41% over the interval, with a maximum amplitude of 16.40%. Meanwhile, the stock's turnover rate over the interval surged from 0.36% to an average of more than 2% per day, producing a textbook low-level, volume-expansion breakout.

According to Smart Finance, on November 11, COFOE MEDICAL closed up only 0.37%, but it formed a shrinking-volume sideways pattern at the tail end of the prior decline, halting the downtrend that had run since November 6 and stabilizing the closing price above the lower Bollinger Band for the day.

In the subsequent sessions from November 12 to 17, the H-shares of COFOE MEDICAL completed a three-stage move within just four trading days: from launch and breakout, to high-level turnover, and then to a second acceleration higher. Looking at the corresponding price-volume behavior, daily volume over those four sessions was 196,000 shares, 719,800 shares, 666,300 shares and 588,700 shares, respectively, displaying a "from interval record volume to shrinking-volume new high" pattern of advancing on declining volume. Cross-validated by the OBV indicator, the metric climbed steadily from 142,900 to 1,594,100, moving fully in sync with the stock's interval price action, with no top divergence between price and volume. To some extent, this indicates that the rally in the H-shares of COFOE MEDICAL was accompanied by easing selling pressure rather than sustained capital withdrawal.

On the technical front, the MACD showed that from November 11 to 17, DIF recovered continuously from -0.607 to -0.097, while DEA rose from -0.588 to -0.406, with the corresponding MACD histogram expanding from -0.038 to 0.617, indicating that bullish momentum for COFOE MEDICAL was accelerating over that interval. As for RSI, although the indicator oscillated upward in the 50-53 range, it never touched the 70 overbought line; moreover, during the November 13 pullback, RSI dipped only to 43.2 (without breaking 50) before recovering to 52.9 on November 16, leaving the RSI bottom-rising structure intact and suggesting that the stock's medium-term momentum remains healthy. By contrast, KDJ continued to spread upward after its golden cross, with the J value above 90 for two consecutive days, constituting a short-term overbought condition.

On November 18, the stock pulled back, with the MACD histogram narrowing slightly to 0.613 — the first shortening of the red bars, indicating marginally weaker momentum — though the overall indicator still pointed to a bullish range. The previously overbought KDJ-J value fell to 75.5 that day and showed a high-level turn lower, further confirming a short-term correction signal for COFOE MEDICAL. Even so, the K value remained above the D value, showing that the KDJ golden-cross structure has not been broken. Combined with the capital direction indicated by OBV, on November 18 the OBV for COFOE MEDICAL remained at 1,460,400; although slightly lower than the prior day, it was still far above the pre-launch level of 142,900, indicating an overall state of net capital inflow.

In summary, although the H-shares of COFOE MEDICAL briefly broke below the 5-day moving average during the November 18 pullback, hitting an intraday low of HK$27.98, the closing price ultimately held the 5-day line at HK$29. That is to say, the current performance of COFOE MEDICAL still looks like a technical retest and confirmation after a surge, and the bullish structure remaining unbroken means the stock may still have room for a second push higher.

When will the sentiment-driven short-term move turn into a reversal trend?

Recently, the fifth batch of industry standard revision plans for 2026 was officially released, with nine industry standards under the jurisdiction of the Brain-Computer Interface Standardization Technical Committee (MIIT/TC4) approved for project initiation. Policy tailwinds have become one of the important factors influencing recent market sentiment.

According to Smart Finance, although COFOE MEDICAL's core business is not involved in brain-computer interface operations, in recent years the company has built a presence in brain-computer interface-related fields through strategic investments: in 2024, it invested in Niulingke Medical, involving an implantable brain-computer interface project; and at the end of 2025, it invested again in Lizhi Intelligence to position itself in non-invasive brain-computer interface robots.

However, the domestic brain-computer interface sector currently exhibits characteristics of "high volatility and strong divergence," and the generalization of the concept has become a major issue for the sector at this stage. For COFOE MEDICAL, this concept is essentially an equity-investment option, and the company has clearly stated that "its contribution to results will be limited in the short term."

In fact, the main factors driving this round of secondary-market sentiment may lie in the recent bottoming-and-rebound trend in the H-shares of COFOE MEDICAL and the third-quarter earnings-driven行情. According to Smart Finance, taking the A-share market as an example, this year's third-quarter reports show that 5,572 companies generated total revenue of RMB 56.66 trillion, up 5.66% year on year, with corresponding net profit attributable to parent of RMB 5.1 trillion, up 8.3% year on year; 73.15% of listed companies were profitable.

According to the 26Q3 financial report disclosed by COFOE MEDICAL after the close on October 29, the company's revenue for the first three quarters reached RMB 3.191 billion, up 33.08% year on year; corresponding net profit attributable to parent was RMB 305 million, up 17.30% year on year. At the same time, the company's comprehensive gross margin for the period reached 56.24%, up 2.88 percentage points year on year. Gross margin for the third quarter alone reached 56.88%. It is evident that the solid fundamental performance shown in the third-quarter report actually provided important support for COFOE MEDICAL's recent market performance.

During the bottoming-and-rebound process in the H-shares of COFOE MEDICAL, southbound capital reversed its previous left-side trading strategy and chose to add positions on the right side in line with the trend. Over a longer time frame, from November 5 to 17, southbound shareholding in COFOE MEDICAL climbed from 21.64% to 23.73%. Based on total H-share capital of 27 million shares, southbound funds net added about 560,000 shares of COFOE MEDICAL over 11 trading days, bringing cumulative holdings to about 6.41 million shares.

In this process, the pace of southbound additions was highly synchronized with the rebound in the H-shares of COFOE MEDICAL. In particular, on November 13, when COFOE MEDICAL recorded interval record volume, southbound funds added 40,200 shares of the company on a single day; and on November 17, when the stock hit a new interval high, the corresponding southbound shareholding ratio jumped to 23.73%.

In fact, the southbound shareholding ratio mainly began to accelerate after the cornerstone lock-up expiry for COFOE MEDICAL on November 5, so it cannot be ruled out that part of the reason some southbound funds increased holdings was to absorb shares during the cornerstone unlock window. But southbound funds also clearly had an actively bullish logic for buying COFOE MEDICAL.

According to Smart Finance, 2027 will be the first commercialization year for COFOE MEDICAL's CGM devices. With the domestic CGM track currently facing the double-edged sword of a import-substitution window and a price war, COFOE MEDICAL's CGM devices may leverage the company's ability to reuse its channel ecosystem and rely on its "shelf-style distribution efficiency" to achieve a corner overtaking with a significantly lower customer acquisition cost per unit than peers.

Because the secondary market has not priced in any CGM expectations for the company in its H-share performance, there may be a large expectation gap, and this could become an important foundation for a future reversal in the company's share price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment